An official website of the United States government
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Trial Status: active
A first in human study to evaluate the safety and preliminary antitumor activity of
BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or
metastatic KRAS mutant solid tumors.
Inclusion Criteria
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Exclusion Criteria
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases
Known hypersensitivity to BBO-11818 or its excipients Other inclusion/exclusion criteria are specified in the protocol.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06917079.
Locations matching your search criteria
United States
California
La Jolla
UC San Diego Moores Cancer Center
Status: Active
Name Not Available
Florida
Tampa
Moffitt Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available
New York
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not Available
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
Utah
Salt Lake City
Huntsman Cancer Institute/University of Utah
Status: Active
Name Not Available
Washington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Status: Approved
Name Not Available
This is an open-label, multi-center, Phase 1 study designed to evaluate the safety,
tolerability, pharmacokinetics, and efficacy of BBO-11818, a pan-KRAS inhibitor, alone
and in combination with pembrolizumab, pembrolizumab +/- cis/carboplatin + pemetrexed,
cetuximab +/- FOLFOX, NALIRIFOX, or Gemcitabine + Nab-paclitaxel in subjects with locally
advanced unresectable or metastatic KRAS mutant solid tumors. The study includes dose
escalation phase and dose expansion phase.
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
